Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5390 participants.

Also called NCT02239120

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 5,390 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02239120
  • EudraCT 2013-003444-24
Other papers using this trial's data
  • Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups Stroke, 2020-06 DOI, PubMed 32404035, PMC7379165 In the PMC Open Access subset under CC BY.
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source The New England journal of medicine, 2019-05-16 DOI, PubMed 31091372
  • Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS Stroke, 2021-03 DOI, PubMed 33504190
  • Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis Stroke, 2021-03 DOI, PubMed 33588594
  • Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial Circulation, 2021-11-30 DOI, PubMed 34649459
  • Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial Journal of the American Heart Association, 2022-06-07 DOI, PubMed 35656979, PMC9238731 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Poland, Portugal, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02239120. Randomized; double masking; primary purpose prevention. Start 2014-11-27 (actual); primary completion 2018-08-14 (actual). Results posted on 2019-09-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Condition
Stroke
Condition
Secondary Prevention
Intervention (Drug)
optional ASA as comedication
Intervention (Drug)
placebo to ASA
Intervention (Drug)
placebo to optional ASA as comedication
Intervention (Drug)
placebo to dabigatran etexilate
Intervention (Drug)
ASA 100 mg
Intervention (Drug)
dabigatran etexilate
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02239120
Content hash
0d0c1dfbcc2377466dd53637d89a059207801b14ee0fe2ae074249445a84cbb2